Global Subdermal Contraceptive Implants Market Size By Type (Jadelle, Sino-implant), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Subdermal Contraceptive Implants Market was valued at USD 1.35 billion in 2023 and is projected to reach USD 2.41 billion by 2031, growing at a CAGR of 7.5% during the forecast period from 2023 to 2031. This market is experiencing significant growth due to rising awareness about long-acting reversible contraceptives (LARCs), increasing global focus on women's reproductive health, and support from government and non-profit initiatives promoting birth control methods. Subdermal contraceptive implants, known for their efficacy, safety, and long-term protection, are increasingly adopted as a preferred birth control solution in both developed and emerging markets.

Drivers:

1. Increasing Demand for Long-Acting Reversible Contraceptives (LARCs):

Women globally are increasingly choosing LARCs for their high efficacy and low maintenance. Subdermal implants provide up to 3–5 years of contraception with a single insertion, making them highly convenient and effective.

2. Government and NGO-Led Family Planning Programs:

Public health initiatives such as FP2020 and UNFPA programs are accelerating access to contraceptives in underserved regions, boosting adoption of subdermal implants.

3. Growing Reproductive Health Awareness:

Increasing awareness among women about reproductive rights and family planning, combined with education campaigns, is promoting informed contraceptive choices.

Restraints:

1. High Cost and Limited Access in Low-Income Regions:

Despite long-term cost-efficiency, the initial cost of implants and insertion services can be prohibitive, especially in underfunded health systems.

2. Concerns Over Side Effects:

Some users report side effects like irregular bleeding, hormonal imbalances, and complications during removal, which may deter adoption.

Opportunity:

1. Expansion in Emerging Markets:

Developing countries, particularly in Asia-Pacific and Africa, are witnessing expanding healthcare infrastructure and increased investment in women’s health—creating robust market opportunities.

2. Technological Advancements in Implant Materials:

Innovation in biodegradable and user-friendly implant technologies presents opportunities for improved adoption and user satisfaction.

Market by System Type Insights:

Based on system type, the Single-Rod Implant Segment dominated the market in 2023. These implants are preferred due to their smaller size, ease of insertion and removal, and proven effectiveness. Their growing availability and lower complication rates are contributing to increased adoption worldwide. The Two-Rod Implant Segment, while effective, is slightly declining due to longer procedure time and higher insertion complexity.

Market by End-Use Insights:

Public Health Clinics and Government Hospitals led the end-use market in 2023, accounting for over 55% of the revenue. The dominance of this segment is due to the widespread distribution of implants through national family planning initiatives. The Private Clinics and Pharmacies segment is expected to witness the fastest growth, especially in urban areas, driven by increasing preference for personalized and discreet reproductive health services.

Market by Regional Insights:

Asia-Pacific held the largest share of the global market in 2023, owing to high population density, growing government efforts for family planning, and increased acceptance of modern contraceptives. Africa is projected to be the fastest-growing market, supported by international aid programs and NGO interventions focused on reducing unintended pregnancies and improving maternal health. Meanwhile, North America and Europe remain mature markets with steady demand driven by better access to healthcare and insurance coverage.

Competitive Scenario:

Leading players in the market include Organon & Co. (Implanon/Nexplanon), Bayer AG, Shanghai Dahua Pharmaceutical Co., Ltd., and Zhejiang Xianju Pharmaceutical Co., Ltd. These companies are focusing on expanding manufacturing capabilities, entering public health tenders, and enhancing implant design for improved comfort and insertion ease.

Key Developments:

In 2023, Organon expanded its global supply agreement with UNFPA to deliver Nexplanon to over 70 low- and middle-income countries.

In 2024, Bayer AG announced research into next-generation subdermal implant materials with lower hormonal doses.

Shanghai Dahua Pharmaceutical scaled production in Asia to meet growing regional demand, aligning with China's national birth control strategies.

Scope of Work – Global Subdermal Contraceptive Implants Market

Report Metric Details

Market Size (2023) USD 1.35 billion

Projected Market Size (2031) USD 2.41 billion

CAGR (2023–2031) 7.5%

Key Segments